PMID- 31269545
OWN - NLM
STAT- MEDLINE
DCOM- 20191211
LR  - 20200225
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 34
IP  - 26
DP  - 2019 Jul 8
TI  - Characterization and Prognostic Significance of Cutaneous Adverse Events to 
      Anti-Programmed Cell Death-1 Therapy.
PG  - e186
LID - 10.3346/jkms.2019.34.e186 [doi]
LID - e186
AB  - BACKGROUND: Anti-programmed cell death-1 (PD-1) immunotherapy using antibodies 
      such as nivolumab or pembrolizumab has shown promise for treating various types 
      of cancer. In this study, we reviewed the frequency and spectrum of cutaneous 
      adverse events (AEs) caused by PD-1 antibodies and their possible correlation 
      with treatment response. METHODS: We reviewed records of all patients from a 
      single institution treated with either nivolumab or pembrolizumab from August 1, 
      2014 to April 1, 2017. RESULTS: Of 211 patients included in the study, 134 
      (63.5%) were treated with nivolumab and 77 (36.5%) with pembrolizumab. 
      Thirty-five patients (16.4%) developed cutaneous AEs. Cutaneous AEs were 
      significantly associated with longer treatment cycles (P = 0.001). The prevalence 
      of cutaneous AEs did not differ between nivolumab (17.2%) and pembrolizumab 
      (15.6%). Patient age, gender, baseline Eastern Cooperative Oncology Group scale 
      and underlying malignancy were not associated with development of cutaneous AEs. 
      Median time until onset of cutaneous AEs was 50.0 days (range, 1-378 days). 
      Anti-PD-1 therapy was tolerable in most of patients with grade 1 (65.2%) and 
      grade 2 (23.9%) cutaneous AEs. Pruritus (32.6%) and eczema (21.7%) were the most 
      commonly reported cutaneous AEs. In lung cancer patients, cutaneous AEs were not 
      associated with better treatment outcomes after adjusting for the number of 
      treatment cycles. CONCLUSION: Both pembrolizumab and nivolumab exhibited 
      tolerable cutaneous safety profiles in a variety of cancer patients undergoing 
      anti-PD-1 therapy. Cutaneous AEs of anti-PD-1 therapy were not associated with 
      antibody type, underlying malignancy, patient characteristics, or improved 
      response.
CI  - (c) 2019 The Korean Academy of Medical Sciences.
FAU - Lee, Ye Jin
AU  - Lee YJ
AUID- ORCID: 0000-0002-3032-2428
AD  - Department of Dermatology, Kyung Hee University Hospital at Gangdong, Seoul, 
      Korea.
FAU - Kim, Hak Tae
AU  - Kim HT
AUID- ORCID: 0000-0002-1359-7876
AD  - Department of Dermatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Won, Chong Hyun
AU  - Won CH
AUID- ORCID: 0000-0003-1997-2240
AD  - Department of Dermatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Chang, Sung Eun
AU  - Chang SE
AUID- ORCID: 0000-0003-4225-0414
AD  - Department of Dermatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Lee, Mi Woo
AU  - Lee MW
AUID- ORCID: 0000-0003-4669-9454
AD  - Department of Dermatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Choi, Jee Ho
AU  - Choi JH
AUID- ORCID: 0000-0001-6139-9869
AD  - Department of Dermatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Lee, Woo Jin
AU  - Lee WJ
AUID- ORCID: 0000-0002-0549-464X
AD  - Department of Dermatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea. uucm79@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20190708
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (Nivolumab)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/*adverse effects/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Immunotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/drug therapy
MH  - Nivolumab/*adverse effects/therapeutic use
MH  - Prognosis
MH  - Programmed Cell Death 1 Receptor/*immunology
MH  - Pruritus/etiology
MH  - Retrospective Studies
MH  - Skin Diseases/*etiology
MH  - Young Adult
PMC - PMC6609422
OTO - NOTNLM
OT  - Anti-programmed Cell Death-1 (PD-1) Therapy
OT  - Cutaneous Adverse Event
OT  - Nivolumab
OT  - Pembrolizumab
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2019/07/04 06:00
MHDA- 2019/12/18 06:00
PMCR- 2019/07/08
CRDT- 2019/07/04 06:00
PHST- 2019/01/21 00:00 [received]
PHST- 2019/06/10 00:00 [accepted]
PHST- 2019/07/04 06:00 [entrez]
PHST- 2019/07/04 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/07/08 00:00 [pmc-release]
AID - 34.e186 [pii]
AID - 10.3346/jkms.2019.34.e186 [doi]
PST - epublish
SO  - J Korean Med Sci. 2019 Jul 8;34(26):e186. doi: 10.3346/jkms.2019.34.e186.